Director/PDMR Share Purchases

Cambridge Cognition Holdings PLC

16 December 2024

 

16 December 2024 

Cambridge Cognition Holdings Plc

("Cambridge Cognition", the "Company" or the "Group")

Director/PDMR Share Purchases

Cambridge Cognition Holdings Plc (AIM: COG), which develops and markets digital solutions to assess brain health, was informed on 13 December 2024 that Stuart Gall, Non-Executive Director of the Company, purchased 31,250 ordinary shares of 0.01 pence each ("Ordinary Shares") in the Company at a price of 32 pence per share.

Following this transaction, Stuart Gall holds an interest in 68,750 Ordinary Shares, representing approximately 0.16% of the Company's issued share capital.

Further information on the purchases is contained in the disclosure tables below.

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM:

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Stuart Gall
2	Reason for the notification
a)	Position/status	Non-Executive Director
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Cambridge Cognition Holdings Plc
b)	LEI	213800SZKDIN122EPA96
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument Identification code	Ordinary shares of 0.01p each GB00B8DV9647
b)	Nature of the transaction	Purchase of Shares
c)	Price(s) and volume(s)	Price(s) Volume(s) 32 pence 31,250
d)	Aggregated information - Aggregated volume - Price	n/a
e)	Date of the transaction	13 December 2024
f)	Place of the transaction	London Stock Exchange

Enquiries:

Cambridge Cognition Holdings plc  Dr Steven Powell, Chairman Tel: [phone]  Hudson Sandler (Financial PR and IR)  Dan de Belder / Hattie Dreyfus / Harry Griffiths Tel: [phone]  [e-mail] Panmure Liberum Limited (NOMAD and Joint Broker)  Will Goode / Freddy Crossley / Mark Rogers   Rupert Dearden  Tel: [phone]  (Corporate Finance)  (Corporate Broking)  Dowgate Capital Limited (Joint Broker)  David Poutney / James Serjeant  Tel: [phone]

Notes to Editors

About Cambridge Cognition

Cambridge Cognition is a leading technology company specializing in digital health products that advance brain health research and treatment. The Company offers three core products: CANTAB® assessments, which provide scientifically validated, highly sensitive, precise, and objective measures of cognitive function correlated to neural networks; a flexible and proven eCOA platform, with a large library of instruments, enabling efficient study set up and scalable data capture; and Quality Assurance Tools that ensure data integrity by automatically detecting deviations in administration and scoring, saving time and money. Together, these products improve clinical trial outcomes, enable early patient identification, and enhance global efficiency in healthcare and pharmaceuticals.

For further information visit: https://cambridgecognition.com/

 

END